CinRx Pharma, LLC - 11 Jan 2022 Form 4 Insider Report for CinCor Pharma, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 11 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2022, 15:40:36 UTC
Prior SEC filing: 10 Jan 2022
Source filing: View source filing
Reporting owner signature: CinRx Pharma, LLC, By /s/ Jonathan Isaacsohn, CEO

Key filing fact

CinRx Pharma, LLC filed Form 4 for CinCor Pharma, Inc. on 13 Jan 2022.

Key facts

This page summarizes CinRx Pharma, LLC's Form 4 filing for CinCor Pharma, Inc..
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jan 2022, 15:40.

Change

Previous filing in this sequence was filed on 10 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CINC transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,222,530
Change %: +51%
Price
Shares after: 3,630,103
Date: 11 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CINC transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -2,142,856
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 630,251
Exercise price
Footnotes: F1

CINC transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -2,013,749
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 592,279
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.